An Update on Biologic Agents Used to Treat Arthritis

BERWYN, Pa. - Continued market growth and expanded indications for biologic medications used to treat arthritis and other conditions have played a significant role in several drug manufacturers' recent sales earnings, the companies and analysts have reported.

Tumor Necrosis Factor-alpha inhibitors Enbrel, Remicade and Humira in particular have expanded therapeutic options for patients with rheumatoid arthritis and psoriatic arthritis. Results from a March survey conducted by BioTrends Research Group Inc. found that physicians expect to increase their use of the drugs in the next six months.

Amgen Inc. and Wyeth reported that sales of Enbrel in the first quarter of …